Cisplatin
Cisplatin (cis-diamminedichloroplatinum(II); CDDP) is a platinum-based cytotoxic chemotherapy drug and one of the foundational agents in medical oncology.
Cisplatin (cis-diamminedichloroplatinum(II); CDDP) is a platinum-based cytotoxic chemotherapy drug and one of the foundational agents in medical oncology. Approved for clinical use in the late 1970s, it is administered intravenously and remains a standard component of regimens for testicular, ovarian, bladder and urothelial, lung, head and neck, and cervical cancers. After entering cells, the chloride ligands are displaced by water, producing a reactive aquated complex that binds genomic DNA and forms intra- and interstrand crosslinks, preferentially at adjacent guanine residues. These adducts distort the DNA helix, stall replication and transcription, and activate the DNA damage response, culminating in cell cycle arrest and apoptosis; TP53 status and signaling through the Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) pathway are among the determinants of how strongly a tumor cell commits to that death program. Although often grouped with alkylating agents because it produces DNA crosslinks, cisplatin is chemically distinct from classical alkylators and acts independently of cell cycle phase. In practice it is rarely used alone, and is combined with gemcitabine, fluorouracil, doxorubicin, methotrexate, paclitaxel, radiation therapy, or immune checkpoint inhibitors such as pembrolizumab, nivolumab, and durvalumab, and it serves as the comparator against which newer regimens such as enfortumab vedotin plus pembrolizumab are measured.
Two problems constrain cisplatin's use: dose-limiting toxicity — nephrotoxicity, ototoxicity, myelosuppression, peripheral neuropathy, and severe emesis — and intrinsic or acquired resistance. Resistance mechanisms studied in tumor cells include elevated intracellular glutathione and other thiol-mediated drug inactivation, enhanced DNA repair capacity, and evasion of regulated cell death. Because cisplatin generates reactive oxygen species and perturbs redox and metal homeostasis, its activity intersects with non-apoptotic death pathways, notably ferroptosis, where Gpx4 and labile iron govern lipid peroxidation, and suppressing ferroptosis defenses can resensitize resistant tumors. Related work explores combination with PARP inhibitors such as olaparib in DNA-repair-deficient tumors, and nanoparticle and micelle formulations that raise platinum loading and direct drug to tumor tissue in order to widen the therapeutic window. Parallel medicinal chemistry efforts develop alternative platinum(II) and other metal complexes intended to retain cytotoxicity, act through mechanisms other than direct DNA targeting, and remain effective in cisplatin-resistant cells.
Where the papers sit
70 papers from the last 6 months study cisplatin directly · updated from PubMed 14 Nov 2026
Study type 3 clinical trials · 9 observational · 3 human data · 48 preclinical · 7 unclassified
Themes 6 themes · 1 paradigm shift · 1 new direction
-
Lung Cancer Drug Resistance
NSCLC treatment is moving toward restoring cisplatin sensitivity by targeting ferroptosis, DNA repair, redox metabolism, and stemness. PCK2 inhibition, LZTFL1, and SIRT6/Nrf2 signaling promote ferroptotic or oxidative stress, while JMJD5 increases DNA damage and ORC1, ZUP1, and SUMOylation-dependent repair sustain resistance. Botanical agents, methionine restriction, and nanocarriers are explored as sensitizers or toxicity-sparing combinations. The work remains mainly mechanistic and preclinical, with no settled dominant strategy.
15 papers · 21.4%
-
Ovarian Platinum Resistance
Ovarian cancer research is shifting from platinum alone toward immune, metabolic, and ferroptosis-informed combinations. VISTA+ neutrophils suppress CD8+ T cells, while IL-6-driven autophagy, SMS1/2, and ZDHHC14–RUNX2–YAP1/GLS1 signaling help explain platinum resistance. Birinapant, natural products, platinum complexes, and cisplatin-loaded hydrogels or nanogels aim to restore killing or improve delivery, including chemoimmunotherapy. The key open question is whether these sensitizers can translate into durable progression-free survival.
14 papers · 20%
-
Cisplatin Toxicity and Protection
Cisplatin toxicity research is converging on mitochondrial injury, oxidative stress, and intrinsic apoptosis, especially in spiral ganglion neurons and kidney. Sphingolipid dysregulation is linked to ototoxicity, while MnTBAP, amifostine-loaded silica, and propolis/Nrf2 signaling are tested for hearing or renal protection. Other studies examine mitochondrial pathways in resistance and ferroptosis, connecting toxicity biology with antitumor response. The field is seeking organ protection without weakening cisplatin activity, but efficacy remains largely preclinical.
10 papers · 14.3%
-
Squamous Cancer Chemoradiotherapy
Squamous head and neck cancer care is being refined around how cisplatin is scheduled with radiotherapy. Randomized trials compare weekly, three-weekly, and divided-dose regimens, with survival, feasibility, nutrition, and geriatric risk shaping selection for older or high-risk patients. Related studies extend the question to nasopharyngeal, esophageal, and oral squamous cancers and to induction chemotherapy. The direction is toward more individualized dose intensity rather than a single universal schedule.
9 papers · 12.9%
-
Tumor Microenvironment and Immunity
Cisplatin-based treatment is being paired with immune- and microenvironment-directed strategies rather than used alone. TTFields and mitochondria-targeted photosensitizers enhance killing and antitumor immunity, while nitric oxide and local hydrogels pursue targeted delivery. In lung adenocarcinoma, DLX6 inhibition sensitizes tumors through GPX4-dependent ferroptosis. The recurring goal is to connect tumor suppression with immune remodeling, although much of the evidence remains preclinical.
7 papers · 10%
-
Others — Cisplatin Response and Delivery
Cisplatin response, resistance, delivery, and renal injury are studied across breast, cervical, urothelial, cholangiocarcinoma, and other cancers. Organoids and multi-omics seek predictive biomarkers, while GALNT6/Smad2/CDC7, SPP1/KRAS, and DNA-repair programs explain resistance in selected tumors. Gemcitabine-based regimens and checkpoint blockade are tested clinically in urothelial and biliary disease, alongside nanocarriers and Pt(IV) prodrugs. Because the cancers and questions do not converge on one biological subject, no single direction dominates.
15 papers · 21.4%
Cisplatin resistance is partly imposed by tissue context, not only encoded within tumor cells
The engineered sulfated-matrix lung-tumor model and the NSCLC tumor–immune models associated with ZUP1 both show that cisplatin response is shaped by the surrounding tissue environment, not solely by tumor-cell-intrinsic resistance machinery. Sulfated extracellular matrices increased stress tolerance and attenuated cisplatin efficacy through PI3K/Akt–ABCB1 signaling, while cisplatin-resistant NSCLC was associated with tumor-microenvironment remodeling and Treg-related signaling, with ZUP1 knockdown tested in resistant cells and tumor–Treg co-cultures 42677696Sep 42722717Sep. This shifts the target of resistance research from cancer-cell pathways alone toward extracellular-matrix and immune-cell interactions that can actively establish or sustain treatment failure.
Cisplatin can provoke a transient sarcoidosis-like inflammatory reaction that mimics metastatic progression
The cervical-cancer case treated with cisplatin-based chemoradiotherapy showed that new FDG-avid lymph-node, bone, and vertebral lesions need not represent cancer progression: biopsy indicated granulomatous inflammation, and the lesions completely resolved without treatment while the primary tumor continued responding. This places cisplatin in an additional role as a trigger of a reversible sarcoidosis-like reaction, altering interpretation of apparent post-treatment dissemination 42665296Aug.
Papers
The 70 papers from the last 6 months that study cisplatin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Lung Cancer Drug Resistance (15)
- Molecular mechanisms of cisplatin-MOF interactions: structure-property relationships for nanoscale drug delivery. Journal of computer-aided molecular design · 6 Nov 2026 PMID 42993327
- Mechanism of ORC1 Regulating Cancer Stemness and Cisplatin Resistance in Non-Small Cell Lung Cancer. Journal of biochemical and molecular toxicology · 25 Sept 2026 PMID 42788364
- SCRMP-mediated SUMOylation of CSNK2B facilitates DNA damage repair to promote cisplatin resistance in small cell lung cancer. Science translational medicine · 23 Sept 2026 PMID 42777084
- Bionic 'Trojan Horse' nanoparticles based on Fe-Cu bimetallic MOFs enhance anti-tumor immunotherapy through multimodal synergistic effects. Journal of materials chemistry. B · 23 Sept 2026 PMID 42775401
- SIRT6 restrains hyperactivated Nrf2 to enhance cisplatin response in lung cancer models. Biochemical and biophysical research communications · 11 Sept 2026 PMID 42727479
- ZUP1 contributes to cisplatin resistance and treg-related signaling in non-small cell lung cancer. Scientific reports · 10 Sept 2026 PMID 42722717
- LncRNA RAMS11-dependent NOTCH3 activation drives tumor progression in non-small cell lung cancer. NAR cancer · 9 Sept 2026 PMID 42712799
- Discovery of novel Quinazoline-chalcone hybrids as dual VEGFR-2/P-gp inhibitors to reverse cisplatin resistance in cervical Cancer. Bioorganic chemistry · 20 Aug 2026 PMID 42623911
- PCK2 Inhibition Reverses Cisplatin Resistance of Non-Small Cell Lung Cancer by Triggering Ferroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 14 Aug 2026 PMID 42599961
- Synergistic anti-cancer activity of Artemisia vulgaris L. aqueous extract with cisplatin against A549 lung cancer cell line. BMC complementary medicine and therapies · 12 Aug 2026 PMID 42581353
- LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis. Molecular cell · 4 Aug 2026 PMID 42551439
- JMJD5 promotes chemotherapy sensitivity of cisplatin in NSCLC by enhancing DNA damage. Biochemical and biophysical research communications · 19 Jul 2026 PMID 42472515
- Insights into hemihydrate nanostructure as a carrier for cisplatin chemotherapy agent: A DFT and AIMD investigation. Journal of molecular graphics & modelling · 16 Jul 2026 PMID 42462326
- Synergy of a Low-methionine Diet and Reduced-dose Cisplatinum Eradicates Experimental Lung-cancer Bone Metastases in a Nude-mouse Model. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379791
- Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1‑mediated suppression of the NLRP3 inflammasome. International journal of molecular medicine · 22 May 2026 PMID 42169649
Ovarian Platinum Resistance (14)
- PMID 42149203
- Influence of cisplatin hydration state on drug delivery efficiency and anticancer activity of heparin-based nanogels. Biochemical and biophysical research communications · 6 Oct 2026 PMID 42837810
- Cisplatin combined with high-intensity focused ultrasound inhibits endometrial cancer progression by inducing pyroptosis. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 26 Sept 2026 PMID 42799609
- Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
- Birinapant enhances cisplatin sensitivity in epithelial ovarian cancer through modulation of apoptotic and survival signaling pathways. Cancer chemotherapy and pharmacology · 8 Sept 2026 PMID 42709209
- E-cadherin-driven interleukin-6 expression promotes autophagy-mediated platinum resistance in ovarian clear cell carcinoma. Cancer gene therapy · 22 Aug 2026 PMID 42632866
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- Dose intensity and clinical outcomes across age groups in high-grade osteosarcoma treated with methotrexate, adriamycin, and cisplatin therapy. Japanese journal of clinical oncology · 26 Jul 2026 PMID 42502976
- Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
- Immunoregulatory Dendritic Lipopeptide Nanoparticles for High-Capacity Cisplatin Delivery and Pancreatic Cancer Chemo-Immunotherapy. ACS applied materials & interfaces · 14 Jul 2026 PMID 42444257
- VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer. Cancer immunology research · 2 Jul 2026 PMID 42390478
- Improving the anticancer efficacy of azole-platinum(II) complexes through a Pluronic® micelle formulation strategy. Dalton transactions (Cambridge, England : 2003) · 2 Jul 2026 PMID 42390168
- Cisplatin-synergistic monoterpene indole alkaloids with diverse scaffolds from Rauvolfia vomitoria. Bioorganic chemistry · 25 Jun 2026 PMID 42348943
- Ligand design controls biomolecule binding and cytotoxicity in platinum(II) complexes with ONS-type tridentate ligands. Dalton transactions (Cambridge, England : 2003) · 23 Jun 2026 PMID 42333610
Cisplatin Toxicity and Protection (10)
- Sphingolipid Metabolic Dysregulation Drives Cisplatin-Induced Ototoxicity Through Mitochondrial Dysfunction and Intrinsic Apoptosis. Free radical biology & medicine · 3 Nov 2026 PMID 42977102
- Otoprotective effect of MnTBAP in cisplatin-induced hearing loss. PloS one · 21 Sept 2026 PMID 42766579
- Propolis ameliorates cisplatin-induced nephrotoxicity via activation of Nrf2/HO-1 signaling pathway in rats. Journal of molecular histology · 21 Sept 2026 PMID 42766218
- A mitochondria-targeted supramolecular nanoplatform overcomes cisplatin resistance via self-amplified ferroptosis. International journal of pharmaceutics · 18 Sept 2026 PMID 42759672
- Cisplatin enhances radiation-induced apoptosis in peripheral lymphocytes of cancer patients: in vivo and in vitro findings. Radiation oncology (London, England) · 6 Sept 2026 PMID 42701199
- Engineered matrices reveal sulfation-mediated stress adaptation and drug-specific modulation of chemotherapeutic response. Biomaterials science · 1 Sept 2026 PMID 42677696
- circBIRC6 regulates cisplatin resistance of choroidal melanoma via positively modulating ERK by sponging miR-503-3p. Molecular biology reports · 28 Aug 2026 PMID 42663723
- Prophylactic administration of silica nanoparticles loaded with amifostine prevents cisplatin-induced nephrotoxicity in rats. Journal of molecular histology · 30 Jul 2026 PMID 42530708
- The Zuo Jin Wan Formula Reverses Cisplatin Resistance in Gastric Cancer by Inhibiting the Mitochondrial Translocation of Dynamin-Related Protein 1 and Its Mediated Mitochondrial Fission and Mitophagy. Cancer medicine · 29 Jul 2026 PMID 42522679
- Mechanistic Exploration of Half-Sandwich Iridium(III) Anticancer Compounds through Integrated Cellular, Proteomic, and In Vivo Analyses. Journal of medicinal chemistry · 16 Jun 2026 PMID 42300762
Squamous Cancer Chemoradiotherapy (9)
- Clinical Outcomes of Postoperative Three-weekly Cisplatin for High-risk Head and Neck Squamous Cell Carcinoma. Anticancer research · 27 Oct 2026 PMID 42946446
- Alternative tobacco and nicotine products during anticancer therapy: a systematic review of mechanistic toxicology evidence, treatment-resistance signals, and potential hazards. Toxicology mechanisms and methods · 14 Sept 2026 PMID 42734481
- The RNA-binding protein La/SSB is associated with HNSCC progression and TFAP2C/FSCN1-linked transcriptional regulation. Oncogene · 4 Sept 2026 PMID 42693251
- Pretreatment Geriatric Nutritional Risk Index in RADPLAT-treated Patients With Oral Squamous Cell Carcinoma: A Pilot Study. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665408
- Cisplatin-induced sarcoidosis-like reaction after primary chemoradiotherapy for locally advanced cervical cancer. BMJ case reports · 28 Aug 2026 PMID 42665296
- Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. NEJM evidence · 25 Aug 2026 PMID 42640170
- Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527061
- Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 26 Jun 2026 PMID 42361282
- A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY). Japanese journal of clinical oncology · 24 Jun 2026 PMID 42341154
Tumor Microenvironment and Immunity (7)
- An Inhalable Hybrid Nitric Oxide Nanogenerator for Lung Adenocarcinoma Treatment via Bioorthogonal-Activated Gas-Immunotherapy. Journal of the American Chemical Society · 9 Sept 2026 PMID 42714559
- Comprehensive study of the tumor immune microenvironment and the prognostic significance of reticulocalbin-1: a pan-cancer analysis. Functional & integrative genomics · 26 Aug 2026 PMID 42645556
- A Robust Mitochondria-Targeted Photosensitizer Synergizes With Cisplatin Chemotherapy for Enhanced Antitumor Immunity. Chemistry (Weinheim an der Bergstrasse, Germany) · 13 Aug 2026 PMID 42593091
- Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis. Cellular oncology (Dordrecht, Netherlands) · 15 Jul 2026 PMID 42455236
- Tumor Treating Fields (TTFields) potentiate cisplatin efficacy and remodel the transcriptional landscape in preclinical models of pancreatic ductal adenocarcinoma. Cancer letters · 13 Jun 2026 PMID 42288239
- Carboxymethyl chitosan/sodium alginate-based dynamic organic nanocomposite hydrogel for local tumoral targeted therapy. Carbohydrate polymers · 2 Jun 2026 PMID 42230041
- Comprehensive bioinformatics analysis of EXOSC family genes in lung adenocarcinoma. Discover oncology · 22 May 2026 PMID 42171853
Others — Cisplatin Response and Delivery (15)
- Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory. Molecular biology reports · 4 Nov 2026 PMID 42980935
- Integrative multi-omics analysis reveals a GALNT6/Smad2/CDC7 axis promoting cisplatin resistance through enhanced DNA damage repair in bladder cancer. Functional & integrative genomics · 3 Nov 2026 PMID 42975739
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957262
- Temporal multi-omics reveals regulatory transitions and renoprotective candidates in cisplatin-induced kidney injury. Molecular & cellular proteomics : MCP · 26 Oct 2026 PMID 42933641
- Integrated in silico and in vitro analysis identifies a co-expression pattern associated with cisplatin/5-FU treatment response and metastatic features in gastric cancer. Molecular biology reports · 16 Oct 2026 PMID 42886301
- Real-world outcomes in circulating tumor DNA-detected isocitrate dehydrogenase 1-mutant cholangiocarcinoma: First-line gemcitabine and cisplatin with versus without immunotherapy. Cancer · 15 Oct 2026 PMID 42876026
- Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model. Cell biology international · 28 Sept 2026 PMID 42803388
- Synthesis, characterization, and in vitro evaluation of diglycolamic acid functionalized graphitic carbon nitride for cisplatin delivery. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 Aug 2026 PMID 42659803
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report. Medicine · 15 Aug 2026 PMID 42601691
- Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer. Cell reports. Medicine · 6 Aug 2026 PMID 42561946
- Chemical aspects of controlled cisplatin release and apoptosis via Nerium oleander latex nano-carriers in breast cancer cells. Drug development and industrial pharmacy · 29 Jul 2026 PMID 42524708
- SPP1 promotes cisplatin resistance in cervical cancer by regulating KRAS expression. PloS one · 27 Jul 2026 PMID 42507688
- A Pt(IV) prodrug for cancer chemo-photodynamic therapy preventing skin photosensitivity via in situ PpIX generation. Chemical communications (Cambridge, England) · 27 Jul 2026 PMID 42504784
- Moonlighting role of meiotic SYCP1 in breast cancer: A chromatin-bound regulator of DNA repair, transcription, and drug resistance. Science advances · 8 Jul 2026 PMID 42418586
- First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
By study type
Clinical trials (3)
- Induction Paclitaxel-Cisplatin-Capecitabine for Nasopharyngeal Carcinoma. NEJM evidence · 25 Aug 2026 PMID 42640170
- Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 26 Jun 2026 PMID 42361282
- A multicenter randomized phase III trial of weekly cisplatin chemoradiotherapy versus radiotherapy in elderly patients with head and neck squamous cell carcinoma unfit for high-dose cisplatin: JCOG2405 (ELDER-WEEKLY). Japanese journal of clinical oncology · 24 Jun 2026 PMID 42341154
Observational studies and case reports (9)
- Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957262
- Clinical Outcomes of Postoperative Three-weekly Cisplatin for High-risk Head and Neck Squamous Cell Carcinoma. Anticancer research · 27 Oct 2026 PMID 42946446
- Cisplatin enhances radiation-induced apoptosis in peripheral lymphocytes of cancer patients: in vivo and in vitro findings. Radiation oncology (London, England) · 6 Sept 2026 PMID 42701199
- Cisplatin-induced sarcoidosis-like reaction after primary chemoradiotherapy for locally advanced cervical cancer. BMJ case reports · 28 Aug 2026 PMID 42665296
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report. Medicine · 15 Aug 2026 PMID 42601691
- Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer research · 29 Jul 2026 PMID 42527061
- Dose intensity and clinical outcomes across age groups in high-grade osteosarcoma treated with methotrexate, adriamycin, and cisplatin therapy. Japanese journal of clinical oncology · 26 Jul 2026 PMID 42502976
- VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer. Cancer immunology research · 2 Jul 2026 PMID 42390478
- First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA network open · 1 Jul 2026 PMID 42384383
Human data, design not indexed (3)
- Real-world outcomes in circulating tumor DNA-detected isocitrate dehydrogenase 1-mutant cholangiocarcinoma: First-line gemcitabine and cisplatin with versus without immunotherapy. Cancer · 15 Oct 2026 PMID 42876026
- Pretreatment Geriatric Nutritional Risk Index in RADPLAT-treated Patients With Oral Squamous Cell Carcinoma: A Pilot Study. In vivo (Athens, Greece) · 28 Aug 2026 PMID 42665408
- Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer. Cell reports. Medicine · 6 Aug 2026 PMID 42561946
Preclinical: animal, cell and lab studies (48)
- Molecular mechanisms of cisplatin-MOF interactions: structure-property relationships for nanoscale drug delivery. Journal of computer-aided molecular design · 6 Nov 2026 PMID 42993327
- Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory. Molecular biology reports · 4 Nov 2026 PMID 42980935
- Integrative multi-omics analysis reveals a GALNT6/Smad2/CDC7 axis promoting cisplatin resistance through enhanced DNA damage repair in bladder cancer. Functional & integrative genomics · 3 Nov 2026 PMID 42975739
- Integrated in silico and in vitro analysis identifies a co-expression pattern associated with cisplatin/5-FU treatment response and metastatic features in gastric cancer. Molecular biology reports · 16 Oct 2026 PMID 42886301
- Influence of cisplatin hydration state on drug delivery efficiency and anticancer activity of heparin-based nanogels. Biochemical and biophysical research communications · 6 Oct 2026 PMID 42837810
- Synergistic Antitumor Effects and Reduced Systemic Toxicity of Berberine Chloride Combined With Cisplatin in a Female BALB/c Mouse Xenograft Model. Cell biology international · 28 Sept 2026 PMID 42803388
- Cisplatin combined with high-intensity focused ultrasound inhibits endometrial cancer progression by inducing pyroptosis. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 26 Sept 2026 PMID 42799609
- Mechanism of ORC1 Regulating Cancer Stemness and Cisplatin Resistance in Non-Small Cell Lung Cancer. Journal of biochemical and molecular toxicology · 25 Sept 2026 PMID 42788364
- SCRMP-mediated SUMOylation of CSNK2B facilitates DNA damage repair to promote cisplatin resistance in small cell lung cancer. Science translational medicine · 23 Sept 2026 PMID 42777084
- Bionic 'Trojan Horse' nanoparticles based on Fe-Cu bimetallic MOFs enhance anti-tumor immunotherapy through multimodal synergistic effects. Journal of materials chemistry. B · 23 Sept 2026 PMID 42775401
- Otoprotective effect of MnTBAP in cisplatin-induced hearing loss. PloS one · 21 Sept 2026 PMID 42766579
- Propolis ameliorates cisplatin-induced nephrotoxicity via activation of Nrf2/HO-1 signaling pathway in rats. Journal of molecular histology · 21 Sept 2026 PMID 42766218
- A mitochondria-targeted supramolecular nanoplatform overcomes cisplatin resistance via self-amplified ferroptosis. International journal of pharmaceutics · 18 Sept 2026 PMID 42759672
- SIRT6 restrains hyperactivated Nrf2 to enhance cisplatin response in lung cancer models. Biochemical and biophysical research communications · 11 Sept 2026 PMID 42727479
- ZUP1 contributes to cisplatin resistance and treg-related signaling in non-small cell lung cancer. Scientific reports · 10 Sept 2026 PMID 42722717
- An Inhalable Hybrid Nitric Oxide Nanogenerator for Lung Adenocarcinoma Treatment via Bioorthogonal-Activated Gas-Immunotherapy. Journal of the American Chemical Society · 9 Sept 2026 PMID 42714559
- LncRNA RAMS11-dependent NOTCH3 activation drives tumor progression in non-small cell lung cancer. NAR cancer · 9 Sept 2026 PMID 42712799
- Green synthesis of CuO nanoparticles using mangrove leaves for targeted delivery of platinum (II) therapeutics. Scientific reports · 9 Sept 2026 PMID 42711436
- Birinapant enhances cisplatin sensitivity in epithelial ovarian cancer through modulation of apoptotic and survival signaling pathways. Cancer chemotherapy and pharmacology · 8 Sept 2026 PMID 42709209
- Engineered matrices reveal sulfation-mediated stress adaptation and drug-specific modulation of chemotherapeutic response. Biomaterials science · 1 Sept 2026 PMID 42677696
- circBIRC6 regulates cisplatin resistance of choroidal melanoma via positively modulating ERK by sponging miR-503-3p. Molecular biology reports · 28 Aug 2026 PMID 42663723
- Synthesis, characterization, and in vitro evaluation of diglycolamic acid functionalized graphitic carbon nitride for cisplatin delivery. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 27 Aug 2026 PMID 42659803
- Comprehensive study of the tumor immune microenvironment and the prognostic significance of reticulocalbin-1: a pan-cancer analysis. Functional & integrative genomics · 26 Aug 2026 PMID 42645556
- E-cadherin-driven interleukin-6 expression promotes autophagy-mediated platinum resistance in ovarian clear cell carcinoma. Cancer gene therapy · 22 Aug 2026 PMID 42632866
- Discovery of novel Quinazoline-chalcone hybrids as dual VEGFR-2/P-gp inhibitors to reverse cisplatin resistance in cervical Cancer. Bioorganic chemistry · 20 Aug 2026 PMID 42623911
- PCK2 Inhibition Reverses Cisplatin Resistance of Non-Small Cell Lung Cancer by Triggering Ferroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 14 Aug 2026 PMID 42599961
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- A Robust Mitochondria-Targeted Photosensitizer Synergizes With Cisplatin Chemotherapy for Enhanced Antitumor Immunity. Chemistry (Weinheim an der Bergstrasse, Germany) · 13 Aug 2026 PMID 42593091
- Synergistic anti-cancer activity of Artemisia vulgaris L. aqueous extract with cisplatin against A549 lung cancer cell line. BMC complementary medicine and therapies · 12 Aug 2026 PMID 42581353
- LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis. Molecular cell · 4 Aug 2026 PMID 42551439
- Prophylactic administration of silica nanoparticles loaded with amifostine prevents cisplatin-induced nephrotoxicity in rats. Journal of molecular histology · 30 Jul 2026 PMID 42530708
- Chemical aspects of controlled cisplatin release and apoptosis via Nerium oleander latex nano-carriers in breast cancer cells. Drug development and industrial pharmacy · 29 Jul 2026 PMID 42524708
- The Zuo Jin Wan Formula Reverses Cisplatin Resistance in Gastric Cancer by Inhibiting the Mitochondrial Translocation of Dynamin-Related Protein 1 and Its Mediated Mitochondrial Fission and Mitophagy. Cancer medicine · 29 Jul 2026 PMID 42522679
- SPP1 promotes cisplatin resistance in cervical cancer by regulating KRAS expression. PloS one · 27 Jul 2026 PMID 42507688
- A Pt(IV) prodrug for cancer chemo-photodynamic therapy preventing skin photosensitivity via in situ PpIX generation. Chemical communications (Cambridge, England) · 27 Jul 2026 PMID 42504784
- JMJD5 promotes chemotherapy sensitivity of cisplatin in NSCLC by enhancing DNA damage. Biochemical and biophysical research communications · 19 Jul 2026 PMID 42472515
- Insights into hemihydrate nanostructure as a carrier for cisplatin chemotherapy agent: A DFT and AIMD investigation. Journal of molecular graphics & modelling · 16 Jul 2026 PMID 42462326
- Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
- Moonlighting role of meiotic SYCP1 in breast cancer: A chromatin-bound regulator of DNA repair, transcription, and drug resistance. Science advances · 8 Jul 2026 PMID 42418586
- Improving the anticancer efficacy of azole-platinum(II) complexes through a Pluronic® micelle formulation strategy. Dalton transactions (Cambridge, England : 2003) · 2 Jul 2026 PMID 42390168
- Synergy of a Low-methionine Diet and Reduced-dose Cisplatinum Eradicates Experimental Lung-cancer Bone Metastases in a Nude-mouse Model. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379791
- Cisplatin-synergistic monoterpene indole alkaloids with diverse scaffolds from Rauvolfia vomitoria. Bioorganic chemistry · 25 Jun 2026 PMID 42348943
- Ligand design controls biomolecule binding and cytotoxicity in platinum(II) complexes with ONS-type tridentate ligands. Dalton transactions (Cambridge, England : 2003) · 23 Jun 2026 PMID 42333610
- Mechanistic Exploration of Half-Sandwich Iridium(III) Anticancer Compounds through Integrated Cellular, Proteomic, and In Vivo Analyses. Journal of medicinal chemistry · 16 Jun 2026 PMID 42300762
- Tumor Treating Fields (TTFields) potentiate cisplatin efficacy and remodel the transcriptional landscape in preclinical models of pancreatic ductal adenocarcinoma. Cancer letters · 13 Jun 2026 PMID 42288239
- Phytochemical characterization, molecular docking, and protective efficacy of Cleome droserifolia against cisplatin-induced testicular toxicity. Journal of ethnopharmacology · 11 Jun 2026 PMID 42276387
- Carboxymethyl chitosan/sodium alginate-based dynamic organic nanocomposite hydrogel for local tumoral targeted therapy. Carbohydrate polymers · 2 Jun 2026 PMID 42230041
- Ginsenoside Rg3 potentiates cisplatin antitumor activity while mitigating nephrotoxicity through SIRT1‑mediated suppression of the NLRP3 inflammasome. International journal of molecular medicine · 22 May 2026 PMID 42169649
Unclassified: not yet indexed with MeSH (7)
- Sphingolipid Metabolic Dysregulation Drives Cisplatin-Induced Ototoxicity Through Mitochondrial Dysfunction and Intrinsic Apoptosis. Free radical biology & medicine · 3 Nov 2026 PMID 42977102
- Temporal multi-omics reveals regulatory transitions and renoprotective candidates in cisplatin-induced kidney injury. Molecular & cellular proteomics : MCP · 26 Oct 2026 PMID 42933641
- Alternative tobacco and nicotine products during anticancer therapy: a systematic review of mechanistic toxicology evidence, treatment-resistance signals, and potential hazards. Toxicology mechanisms and methods · 14 Sept 2026 PMID 42734481
- The RNA-binding protein La/SSB is associated with HNSCC progression and TFAP2C/FSCN1-linked transcriptional regulation. Oncogene · 4 Sept 2026 PMID 42693251
- Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis. Cellular oncology (Dordrecht, Netherlands) · 15 Jul 2026 PMID 42455236
- Immunoregulatory Dendritic Lipopeptide Nanoparticles for High-Capacity Cisplatin Delivery and Pancreatic Cancer Chemo-Immunotherapy. ACS applied materials & interfaces · 14 Jul 2026 PMID 42444257
- Comprehensive bioinformatics analysis of EXOSC family genes in lung adenocarcinoma. Discover oncology · 22 May 2026 PMID 42171853
Written from 70 PubMed abstracts, each one listed by PMID above. Published: 2026-06-13. Last written: 2026-09-25 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.